Fragment-Based Discovery and Structure-Led Optimization of MSC778, the First Potent, Selective, and Orally Bioavailable FEN1 Inhibitor.
Mann SE, Lefranc J, Alkhatib O, Boivin R, Bomke J, Byrne RT, Cassona CP, Chen X, Cornaciu I, Costales P, Davis OA, DeSelm L, Elinati E, Follows B, Galbiati A, Göldner C, Hayre JK, Jorand-Lebrun C, Lademann CA, Leuthner B, Majithiya JB, Malta CF, Mason B, McWhirter CL, Neff B, Nissink JWM, Pehl U, Petersson C, Pica A, Pinto MF, Rajendra E, Rakers C, Toste Rêgo A, Robinson HMR, Sala-Hojman A, Schaedler TA, Schürmann PJL, Silva DO, Smith GCM, Sorrell F, Webster GR, Zenke FT, Heald RA, Burgdorf LT.
Mann SE, et al. Among authors: webster gr.
J Med Chem. 2025 Oct 9;68(19):20410-20434. doi: 10.1021/acs.jmedchem.5c01526. Epub 2025 Sep 17.
J Med Chem. 2025.
PMID: 40963090